keyword
MENU ▼
Read by QxMD icon Read
search

HDL HIV

keyword
https://www.readbyqxmd.com/read/28648475/effects-of-docosahexanoic-acid-on-metabolic-and-fat-parameters-in-hiv-infected-patients-on-cart-a-randomized-double-blind-placebo-controlled-study
#1
Pere Domingo, Irene Fernández, José Miguel Gallego-Escuredo, Ferran Torres, Ma Del Mar Gutierrez, Ma Gracia Mateo, Joan Villarroya, Marta Giralt, Francesc Vidal, Francesc Villarroya, Joan Carles Domingo
BACKGROUND: Hypertriglyceridemia is common in HIV-infected patients. Polyunsaturated fatty acids reduce fasting serum triglyceride (TG) levels in HIV-infected patients. It is not known whether docosahexanoic acid (DHA) supplementation can reduce hypertriglyceridemia and modify fat distribution in HIV-infected patients. METHODS: We conducted a randomized, double-blind, placebo-controlled trial with 84 antiretroviral-treated patients who had fasting TG levels from 2...
June 8, 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/28623554/-obesity-high-blood-pressure-hypercholesterolaemia-and-untreated-diabetes-in-hiv-infected-and-hiv-uninfected-adults-in-mbuji-mayi-democratic-republic-of-congo
#2
D Mukeba-Tshialala, J B Nachega, M Mutombo-Tshingwali, V Arendt, G Gilson, M Moutschen
Little is known about the major cardiovascular risk factors in HIV-infected as compared to the HIV-uninfected patients in the Democratic Republic of Congo (DR Congo). We determined the prevalence of hypertension, obesity (BMI ≥ 30 kg/m(2)), total cholesterol > 200 mg/dl, HDL-cholesterol ≤ 40 mg/dl, and glycemia > 126 mg/dl. We also calculated the average and/or median of total cholesterol, HDL-cholesterol, and glycemia among HIV-infected and HIV-uninfected patients. We conducted a cross-sectional study that enrolled 592 HIV-uninfected and 445 HIV-infected patients of whom 425 (95...
June 16, 2017: Bulletin de la Société de Pathologie Exotique
https://www.readbyqxmd.com/read/28599673/low-hdl-cholesterol-among-hiv-1-infected-and-hiv-1-uninfected-individuals-in-nairobi-kenya
#3
Anne Njoroge, B L Guthrie, Rose Bosire, Mark Wener, James Kiarie, Carey Farquhar
BACKGROUND: Antiretroviral treatment (ART) is associated with dyslipidemia yet little is known about the burden of dyslipidemia in the absence of ART in sub-Saharan Africa. We compared the prevalence and risk factors for dyslipidemia among HIV-infected ART-naïve adults and their uninfected partners in Nairobi, Kenya. METHODS: Non-fasting total cholesterol (TC) and high density lipoprotein cholesterol (HDL) levels were measured by standard lipid spectrophotometry on thawed plasma samples obtained from HIV-infected participants and their uninfected partners...
June 9, 2017: Lipids in Health and Disease
https://www.readbyqxmd.com/read/28522147/cardiovascular-risk-in-advanced-na%C3%A3-ve-hiv-infected-patients-starting-antiretroviral-therapy-comparison-of-three-different-regimens-prevaleat-ii-cohort
#4
Paolo Maggi, Chiara Bellacosa, Armando Leone, Anna Volpe, Elena Delfina Ricci, Nicoletta Ladisa, Stefania Cicalini, Elisabetta Grilli, Rosaria Viglietti, Antonio Chirianni, Lara Ines Bellazzi, Renato Maserati, Canio Martinelli, Paola Corsi, Benedetto Maurizio Celesia, Federica Sozio, Gioacchino Angarano
BACKGROUND AND AIMS: PREVALEAT (PREmature VAscular LEsions and Antiretroviral Therapy) II is a multicenter, longitudinal cohort study aimed at the evaluation of cardiovascular risk among advanced HIV-positive, treatment-naïve patients starting their first therapy. We hypothesized that these patients, present a higher cardiovascular (CV) risk. METHODS: The study included all consecutive naïve patients with less than 200 CD4 cells/ml starting antiretroviral therapy...
May 5, 2017: Atherosclerosis
https://www.readbyqxmd.com/read/28513635/the-impact-of-dark-chocolate-intake-on-arterial-elasticity-in-individuals-with-hiv-aids-undergoing-art-a-randomized-double-blind-crossover-trial
#5
Andrea Mariana Nunes da Costa Teixeira, Liania Alves Luzia, Suelen Jorge de Souza, Aline de Almeida Petrilli, Patrícia de Moraes Pontilho, Jose Maria Pacheco de Souza, Aluísio Augusto Cotrim Segurado, Priscila Efraim, Camila de Melo Picone, Patrícia Helen de Carvalho Rondo
An increase in the frequency of cardiovascular diseases has been observed in the HIV/AIDS population. Studies involving healthy subjects or subjects with other diseases have shown benefits of chocolate supplementation on endothelial function and vasodilation. We evaluate the impact of chocolate consumption on arterial elasticity in people living with human immunodeficiency virus - PLHIV. A double-blind, crossover trial including 110 PLHIV (19 to 59 years) on antiretroviral therapy - ART for at least 6 months and with a viral load of <500 copies per mL was conducted...
May 17, 2017: Food & Function
https://www.readbyqxmd.com/read/28453572/assessment-of-coronary-artery-calcium-by-chest-ct-compared-with-ekg-gated-cardiac-ct-in-the-multicenter-aids-cohort-study
#6
Divay Chandra, Aman Gupta, Joseph K Leader, Meghan Fitzpatrick, Lawrence A Kingsley, Eric Kleerup, Sabina A Haberlen, Matthew J Budoff, Mallory Witt, Wendy S Post, Frank C Sciurba, Alison Morris
RATIONALE: Individuals with HIV are at increased risk for coronary artery disease (CAD). Early detection of subclinical CAD by assessment of coronary artery calcium (CAC) may help risk stratify and prevent CAD events in these individuals. However, the current standard to quantify CAC i.e. Agatston scoring requires EKG-gated cardiac CT imaging. OBJECTIVE: To determine if the assessment of CAC using non-EKG-gated chest CT and the Weston scoring system is a useful surrogate for Agatston scores in HIV-infected and HIV-uninfected individuals...
2017: PloS One
https://www.readbyqxmd.com/read/28447585/metabolic-profiles-of-individuals-switched-to-second-line-antiretroviral-therapy-after-failing-standard-first-line-therapy-for-treatment-of-hiv-1-infection-in-a-randomized-controlled-trial
#7
Amanda H Yao, Cecilia L Moore, Poh Lian Lim, Jean-Michel Molina, Juan Sierra Madero, Stephen Kerr, Paddy Wg Mallon, Sean Emery, David A Cooper, Mark A Boyd
BACKGROUND: To investigate metabolic changes associated with second-line antiretroviral therapy (ART) following virological failure of first-line ART. METHODS: SECOND-LINE was an open-label randomized controlled trial. Participants were randomized 1:1 to receive ritonavir-boosted lopinavir (LPV/r) with 2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI-group) or raltegravir (RAL-group) Two hundred and ten participants had a dual energy X-ray absorptiometry (DXA)-scan at baseline, week 48 and 96...
April 27, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28437620/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-guidelines-for-management-of-dyslipidemia-and-prevention-of-cardiovascular-disease
#8
Paul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, George Grunberger, Chris K Guerin, David S H Bell, Jeffrey I Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A Brinton, Sergio Fazio, Michael Davidson
OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). METHODS: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols...
April 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28424436/-dyslipidemia-and-cardiovascular-risk-assessment-in-hiv-positive-patients
#9
Serhat Uysal, Mürşide Tuncel Başoğlu, Bahar Boydak, Deniz Gökengin
OBJECTIVE: Dyslipidemia is a major complication of antiretroviral treatment. Aim of the present study was to screen baseline lipid levels and cardiovascular disease risk in HIV-positive patients and analyze change in those parameters after initiation of antiretroviral treatment (ART). METHODS: HIV-positive patients who presented at our clinic between April 2011 and August 2012 were included. Study included 19 female (22.1%) and 67 male (77.9%) patients (mean age 39...
March 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28346318/predictors-of-impaired-hdl-function-in-hiv-1-infected-compared-to-uninfected-individuals
#10
Theodoros Kelesidis, Michael N Oda, Mark S Borja, Yumin Yee, Kit F Ng, Diana Huynh, David Elashoff, Judith S Currier
OBJECTIVE: High-density lipoprotein (HDL) function rather than absolute level may be a more accurate indicator for cardiovascular disease (CVD). Novel methods can measure HDL function using patient samples. The objective of this study is to identify factors that may contribute to HDL dysfunction in chronic treated HIV-1 infection. DESIGN: Retrospective study of HDL function measured in 2 ways in HIV-1-infected men with low overall CVD risk and healthy men with no known CVD risk matched by race to the HIV-1-infected participants...
July 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28121706/greater-remnant-lipoprotein-cholesterol-reduction-with-pitavastatin-compared-with-pravastatin-in-hiv-infected-patients
#11
Parag H Joshi, P Elliott Miller, Seth S Martin, Steven R Jones, Joseph M Massaro, Ralph B D'Agostino, Krishnaji R Kulkarni, Craig Sponseller, Peter P Toth
OBJECTIVE: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in those with HIV. An emerging CVD risk factor is triglyceride-rich remnant lipoprotein cholesterol (RLP-C: the sum of intermediate-density lipoprotein and very low-density lipoprotein cholesterol). The effects of statin therapy on lipoprotein subfractions, including RLP-C, in HIV dyslipidemia are unknown. METHODS: This is a post hoc analysis of the randomized INTREPID trial (NCT 01301066) comparing pitavastatin 4 mg daily vs...
April 24, 2017: AIDS
https://www.readbyqxmd.com/read/28107484/resveratrol-co-treatment-attenuates-the-effects-of-hiv-protease-inhibitors-on-rat-body-weight-and-enhances-cardiac-mitochondrial-respiration
#12
Burger Symington, Rudo F Mapanga, Gavin R Norton, M Faadiel Essop
Since the early 1990s human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) emerged as a global health pandemic, with sub-Saharan Africa the hardest hit. While the successful roll-out of antiretroviral (ARV) therapy provided significant relief to HIV-positive individuals, such treatment can also elicit damaging side-effects. Here especially HIV protease inhibitors (PIs) are implicated in the onset of cardio-metabolic complications such as type-2 diabetes and coronary heart disease. As there is a paucity of data regarding suitable co-treatments within this context, this preclinical study investigated whether resveratrol (RSV), aspirin (ASP) or vitamin C (VitC) co-treatment is able to blunt side-effects in a rat model of chronic PI exposure (Lopinavir/Ritonavir treatment for 4 months)...
2017: PloS One
https://www.readbyqxmd.com/read/28011249/lack-of-effects-of-statins-on-high-density-lipoprotein-subfractions-in-hiv-1-infected-patients-receiving-protease-inhibitors
#13
Randa Bittar, Élisabeth Aslangul, Philippe Giral, Lambert Assoumou, Marc-Antoine Valantin, Olga Kalmykova, Marie-Christine Federspiel, Corinne Cherfils, Dominique Costagliola, Dominique Bonnefont-Rousselot
BACKGROUND: We evaluated the effect of 45 days of rosuvastatin or pravastatin treatment on the distribution of HDL subfractions in HIV-1-infected individuals receiving boosted protease inhibitors (PIs) with cardiovascular risk. METHODS: The distribution of HDL subclasses by gradient gel electrophoresis was blindly assessed in 74 HIV-1-infected individuals receiving boosted PIs at baseline and at day 45 of statin treatment, and compared with the distribution obtained in 63 healthy normolipidemic individuals taken as controls...
February 2017: Comptes Rendus Biologies
https://www.readbyqxmd.com/read/27999056/switching-from-a-ritonavir-boosted-pi-to-dolutegravir-as-an-alternative-strategy-in-virologically-suppressed-hiv-infected-individuals
#14
Eugènia Negredo, Vicente Estrada, Pere Domingo, Maria Del Mar Gutiérrez, Gracia M Mateo, Jordi Puig, Anna Bonjoch, Arelly Ornelas, Patricia Echeverría, Carla Estany, Jessica Toro, Bonaventura Clotet
Background: Switching from PIs to dolutegravir in virologically suppressed HIV-infected individuals has not been assessed. Objectives: The principal aim was to assess the evolution of bone mineral density (BMD) when switching from a ritonavir-boosted PI to dolutegravir in HIV-infected patients with osteopenia or osteoporosis. The secondary objective was to assess the antiviral efficacy and safety of the switch therapy. Methods: This randomized, multicentre study assessed changes in BMD, bone turnover markers, and antiviral efficacy and safety in 73 virologically suppressed patients with osteopenia/osteoporosis taking a ritonavir-boosted PI plus abacavir/lamivudine who were randomized to switch from PI to dolutegravir (DOLU group, n  =   37) or continue with a PI (PI group, n  =   36)...
March 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27979047/statin-therapy-and-low-density-lipoprotein-cholesterol-reduction-in-hiv-infected-individuals-after-acute-coronary-syndrome-results-from-the-pacs-hiv-lipids-substudy
#15
MULTICENTER STUDY
Franck Boccara, Joe Miantezila Basilua, Murielle Mary-Krause, Sylvie Lang, Emmanuel Teiger, Philippe Gabriel Steg, Christian Funck-Brentano, Pierre-Marie Girard, Dominique Costagliola, Ariel Cohen, Marguerite Guiguet
Knowledge about lipid interventions in secondary prevention in HIV-infected individuals is limited; studies are sparse. METHODS: A prospective observational multicenter study enrolled 282 patients on statin 1 month after first acute coronary syndrome (ACS) (95 HIV-infected individuals, 187 HIV-uninfected). Data on fasting lipids (total cholesterol [TC], low-density lipoprotein cholesterol, high-density lipoprotein cholesterol [HDL-C], non-HDL-C, triglycerides, TC/HDL-C ratio) were collected over 3 years...
January 2017: American Heart Journal
https://www.readbyqxmd.com/read/27956833/inflammation-modulating-cytokine-profile-and-lipid-interaction-in-hiv-related-risk-factors-for-cardiovascular-diseases
#16
Elizabeth Gori, Takafira Mduluza, Mudavanhu Nyagura, Babill Stray-Pedersen, Zvenyika Alfred Gomo
HIV infection and antiretroviral therapy (ART) are associated with changes in plasma levels of lipoproteins, thus posing the risk of cardiovascular complications in infected individuals. The alteration in plasma lipoprotein levels results from dysregulation of inflammation-modulating cytokines that control lipid metabolism. Little is understood regarding the relationship between the cytokines and serum lipid levels, which have been reported to be altered in adults receiving ART. The objective of this study was to describe the profiles of inflammation-modulating cytokines and their relationship to lipids as cardiovascular disease (CVD) risk factors in HIV infection...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27951755/comparative-effectiveness-of-tenofovir-in-hiv-infected-treatment-experienced-patients-systematic-review-and-meta-analysis
#17
Hannah Ewald, Marilia Santini-Oliveira, Julian-Emanuel Bühler, Danielle Vuichard, Stefan Schandelmaier, Marcel Stöckle, Matthias Briel, Heiner C Bucher, Lars G Hemkens
BACKGROUND: Antiretroviral therapy (ART) regimens for HIV infection are frequently changed. We conducted a systematic review of randomized trials (RCTs) on the benefits and harms of switching to tenofovir disoproxil fumarate (TDF)-based regimens in ART-experienced patients. METHODS: We included RCTs in HIV-infected adults comparing switching to a TDF-containing regimen with maintaining or switching to another regimen. We searched MEDLINE, EMBASE, CENTRAL, LILACS, SCI, and the WHO Global Health Library...
January 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/27904105/evaluation-of-the-lipid-concentrations-after-switching-from-antiretroviral-drug-tenofovir-disoproxil-fumarate-emtricitabine-to-abacavir-sulfate-lamivudine-in-virologically-suppressed-human-immunodeficiency-virus-infected-patients
#18
Hirotaka Arae, Masao Tateyama, Hideta Nakamura, Daisuke Tasato, Kaoru Kami, Kyoko Miyagi, Saori Maeda, Hitoshi Uehara, Makiko Moromi, Katsunori Nakamura, Jiro Fujita
Objective Recently, tenofovir disoproxil fumatate (TDF)-related side effects, such as renal nephrotoxicity and reduction of bone mineral density, have been reported. Consequently, increased switching from fixed-dose tablet TDF and emtricitabine (TDF/FTC) to abacavir and lamivudine (ABC/3TC) has occurred. Interestingly, while TDF has a lipid-lowering property, one of the ABC-related side effects is hyperlipidemia. Therefore, such switching could cause lipid elevation. To evaluate the change in lipid levels associated with switching from TDF/FTC to ABC/3TC in virologically-suppressed human immunodeficiency virus (HIV)-infected patients...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27864732/impact-of-pharmaceutical-care-on-cardiovascular-risk-among-older-hiv-patients-on-antiretroviral-therapy
#19
Elza Aparecida Machado Domingues, Mónica Ferrit-Martín, Miguel Ángel Calleja-Hernández
Background Advances in the treatment of HIV infection have enabled better control of the disease, allowing patients to enjoy a longer life expectancy. However, the ageing of patients leads to an increased prevalence of cardiovascular disease. Various studies have found that pharmaceutical care results in better control of cardiovascular risk factors. Objective To measure the impact of pharmaceutical care on cardiovascular risk in patients older than 50 years receiving combination antiretroviral therapy. Setting Outpatient pharmacy service of a tertiary hospital, Spain...
February 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/27822124/changes-in-coronary-heart-disease-risk-profiles-of-hiv-patients-in-zimbabwe-over-9-months-a-follow-up-study
#20
Danai Tavonga Zhou, Olav Oektedalen, Sandra Shawarira-Bote, Babill Stray-Pedersen
Dyslipidemia, hypertension, inflammation, and coronary heart disease (CHD) are adverse events in human immunodeficiency virus (HIV)-infected patients even if they are receiving antiretroviral therapy (ART). Yet, data on CHD risk induced by HIV or ART in sub-Saharan Africa are limited. The aim of this longitudinal study was to describe changes in CHD risk profiles measured by lipids, inflammatory markers, and Framingham scores among HIV-positive patients previously reported from Harare, Zimbabwe. Patients were grouped into ART-experienced patients (n=147) and ART-naïve patients (n=23) and followed up for 9 months...
2016: HIV/AIDS: Research and Palliative Care
keyword
keyword
30100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"